Cue Biopharma, Inc. · LS:A426PN

Cue Biopharma, Inc. financial statements

Cue Biopharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue27.5M9.29M5.49M1.25M14.9M3.15M3.46M1.14M00
Cost of revenue3.48M2.35M38.1M1.81M-1.78M33.5M27.5M28.5M419.6K202.1K
Gross profit27.5M9.29M-32.6M1.25M14.9M-30.4M3.46M-27.4M-419.6K-202.1K
Research and development37.7M36.3M40.8M38.6M41.3M33.5M27.5M28.5M18.9M5.69M
Selling, general and administrative16.2M14.6M16.7M16.2M17.3M14.7M12.7M11.3M4.33M1.97M
Operating income-26.6M-41.5M-52.1M-53.2M-43.7M-45.0M-36.8M-38.7M-23.2M-7.66M
Depreciation and amortization958.0K397.0K556.0K922.0K1.26M1.06M810.8K760.0K419.6K202.1K
EBITDA-25.6M-41.1M-51.6M-52.3M-42.5M-44.0M-36.0M-37.9M-22.8M-7.46M
Interest expense100.0K100.0K100.0K109.0K1.73M463.9K5.65M000
Income before tax-26.1M-40.7M-50.7M-53.0M-43.7M-44.6M-36.3M-38.2M-23.2M-7.66M
Income tax500.0K03.27M0495.0K206.3K412.5K825.0K00
Net income-26.6M-40.7M-50.7M-53.0M-44.2M-44.8M-36.7M-39.0M-23.2M-7.66M
Earnings per share, basic-0.28-0.72-1.11-1.49-1.41-1.56-1.66-1.94-2.16-11.13
Earnings per share, diluted-0.28-0.72-1.11-1.49-1.41-1.56-1.66-1.94-2.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents27.1M22.5M48.5M51.6M64.4M74.9M44.3M20.8M63.5M14.9M
Short-term investments0024.7M010.0M15.1M18.4M050.0K
Receivables5.55M945.0K1.70M57.0K3.14M1.42M754.9K852.4K
Inventory11115.1M225.5K
Current assets37.0M25.1M51.5M77.2M68.5M87.5M61.0M40.6M65.1M15.1M
Property, plant and equipment241.0K471.0K795.0K1.50M2.11M2.11M1.85M2.78M1.69M1.02M
Total assets42.2M32.2M61.5M91.3M83.4M99.5M71.6M45.4M67.0M16.3M
Accounts payable3.95M2.82M3.50M2.73M2.59M2.07M882.7K2.04M1.66M523.8K
Current liabilities13.5M13.7M17.1M11.5M12.8M16.3M11.7M6.22M5.35M1.07M
Long-term debt04.20M8.04M0
Total debt4.20M37.0K4.04M8.07M07.15M5.80M2.50M
Total liabilities15.8M14.7M24.4M25.6M17.9M20.6M17.0M11.4M5.35M1.10M
Shareholders' equity26.4M17.5M37.1M65.7M65.5M78.9M54.6M34.0M61.6M15.2M
Shares outstanding3.22M61.8M47.2M47.2M32.2M30.4M26.6M20.7M19.5M688.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-21.7M-36.3M-40.0M-41.8M-38.8M-32.5M-30.8M-26.4M-12.1M-5.97M
Capital spending-177.0K-66.0K0-171.0K-913.0K-595.3K-46.4K-1.85M-1.03M-516.0K
Free cash flow-21.9M-36.4M-40.0M-42.0M-39.8M-33.1M-30.8M-28.3M-13.2M-6.48M
Cash from investing75.0K32.0K25.0M-24.6M9.11M4.46M3.45M-20.4M-1.20M-516.0K
Cash from financing26.3M10.2M11.9M53.7M19.2M58.6M50.8M4.18M62.0M15.0M
Dividends paid-199.9K
Share buybacks0-200.0K-750.1K-271.1K-91.0K4.18M-4.16M-1.41M
Change in cash4.68M-26.1M-3.10M-12.8M-10.5M30.6M23.4M-42.6M48.7M8.52M